1. Home
  2. MCS vs ADCT Comparison

MCS vs ADCT Comparison

Compare MCS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marcus Corporation (The)

MCS

Marcus Corporation (The)

HOLD

Current Price

$19.40

Market Cap

590.8M

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.26

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCS
ADCT
Founded
1935
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
590.8M
484.4M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
MCS
ADCT
Price
$19.40
$4.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$23.33
$7.75
AVG Volume (30 Days)
121.0K
830.6K
Earning Date
04-30-2026
05-13-2026
Dividend Yield
1.66%
N/A
EPS Growth
N/A
30.86
EPS
0.77
N/A
Revenue
$758,458,000.00
$81,357,000.00
Revenue This Year
$12.05
N/A
Revenue Next Year
$3.15
$66.49
P/E Ratio
$25.74
N/A
Revenue Growth
3.11
14.85
52 Week Low
$12.85
$1.23
52 Week High
$20.02
$4.98

Technical Indicators

Market Signals
Indicator
MCS
ADCT
Relative Strength Index (RSI) 64.57 59.20
Support Level $14.66 $3.28
Resistance Level N/A $4.32
Average True Range (ATR) 0.59 0.25
MACD 0.09 0.07
Stochastic Oscillator 78.22 58.46

Price Performance

Historical Comparison
MCS
ADCT

About MCS Marcus Corporation (The)

Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: